ArticleJournal of the American Society of Nephrology : JASN2022
Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Article in Journal of the American Society of Nephrology : JASN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05734794 (Study of Rituximab Monotherapy VS Steroid Therapy on Children With New-onset Nephrotic Syndrome), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Rituximab Monotherapy VS Steroid Therapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Rituximab-induced hypogammaglobulinemia in childhood nephrotic syndrome: a systematic review and meta-analysis.European journal of pediatrics · 2026Pooled it
- Steroid-sparing drugs in children and young adults with nephrotic syndrome: a target trial emulation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Trial
- The efficacy and safety of rituximab monotherapy in the new onset pediatric idiopathic nephrotic syndrome: a randomized controlled clinical trial.Renal failure · 2025Trial
- Combined impact of rituximab and target care on efficacy, quality of life, adverse reactions and recurrence rate in children with nephrotic syndrome: a randomized controlled trial.BMC pediatrics · 2025Trial
- [Efficacy and safety of low-dose rituximab in treatment of pediatric nephrotic syndrome: a prospective randomized controlled trial].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023Trial
- Pursuing the optimal strategy for immunosuppression discontinuation in children treated with rituximab for frequently relapsing, steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases.Pediatric nephrology (Berlin, Germany) · 2026Review
- A qualitative study on treatment decision-making experiences of primary caregivers of children with difficult-to-treat nephrotic syndrome.International urology and nephrology · 2026Article
- B cell depletion with rituximab in children with steroid-sensitive nephrotic syndrome: does depletion duration change outcome?Pediatric nephrology (Berlin, Germany) · 2026Article
- Hypogammaglobulinemia and B cell repopulation after rituximab in childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Evaluation of the comparative efficacy and safety of obinutuzumab and other follow-up strategies after rituximab failure in refractory nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Article
- Recent key advances in the understanding of the pathogenesis of childhood minimal change disease.Childhood kidney diseases · 2026Review
- Balancing Benefits and Risks of Rituximab in Pediatric Idiopathic Nephrotic Syndrome: The Critical Role of Age.Kidney international reports · 2026Article
- Efficacy and Safety of Rituximab Therapy to Sustain Remission in Young Children With Childhood Nephrotic Syndrome.Kidney international reports · 2026Article
- Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome.Kidney international reports · 2026Article
- A Focused Comparative Review of Innovative Therapeutics Across Autoimmune and Chronic Inflammatory Diseases.Life (Basel, Switzerland) · 2026Review
- Anti-nephrin antibodies in pediatric nephrotic syndrome: a new paradigm.Pediatric nephrology (Berlin, Germany) · 2026Review
- B-cell-targeting therapies in podocytopathies.Pediatric nephrology (Berlin, Germany) · 2026Review
- The safety of rituximab in pediatric nephrotic syndrome patients: a pharmacovigilance study of the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The efficacy of rituximab in pediatric patients with steroid-dependent or frequent relapsing nephrotic syndrome due to MCD or FSGS.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 18 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong-term outcomes after multiple courses of rituximab among children with frequently relapsing, steroid-dependent nephrotic syndrome (FRSDNS) are unknown.
methodsA retrospective cohort study at 16 pediatric nephrology centers from ten countries in Asia, Europe, and North America included children with FRSDNS who received two or more courses of rituximab. Primary outcomes were relapse-free survival and adverse events.
resultsA total of 346 children (age, 9.8 years; IQR, 6.6-13.5 years; 73% boys) received 1149 courses of rituximab. A total of 145, 83, 50, 28, 22, and 18 children received two, three, four, five, six, and seven or more courses, respectively. Median (IQR) follow-up was 5.9 (4.3-7.7) years. Relapse-free survival differed by treatment courses (clustered log-rank test
conclusionsChildren receiving repeated courses of rituximab for FRSDNS experience an improving clinical response. Side effects appear acceptable, but significant complications can occur. These findings support repeated rituximab use in FRSDNS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.